Abiopharma

New Form 8-K - Microbot Medical Inc. Filed: 2025-09-08 AccNo: 0001641172-25-026815 Size: 237 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

New Form 6-K - I-Mab Filed: 2025-09-08 AccNo: 0000950170-25-113369 Size: 22 MB

Spectral Medical Sponsors Unite for Sepsis Symposium, Chicago September 8 – 9, 2025

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-09-08 AccNo: 0001575872-25-000562 Size: 108 KB

New Form 8-K - Prime Medicine, Inc. Filed: 2025-09-08 AccNo: 0001894562-25-000056 Size: 6 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Guardant Health, Inc. - Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

New Form 8-K - Keros Therapeutics, Inc. Filed: 2025-09-08 AccNo: 0001664710-25-000081 Size: 220 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

New Form 6-K - ALTERITY THERAPEUTICS LTD Filed: 2025-09-08 AccNo: 0001213900-25-085292 Size: 61 KB

New Form 8-K - Dianthus Therapeutics, Inc. /DE/ Filed: 2025-09-08 AccNo: 0001193125-25-197751 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting